Lonza Group Ltd announces that it has completed its acquisition of MODA Technology Partners as of 18 May 2010. The transaction was announced on 12 May 2010.
Through the additional offering of MODA technology, Lonza continues the strategic expansion of its Rapid Testing Solutions, Informatics platform in existing markets, such as the pharmaceutical arena, and allows entry into new market segments. MODA technology provides paperless, quality control solutions for regulated, manufacturing processes. The same user benefits that MODA technology provides can be applied to clinical trials, in-vitro diagnostics, food, beverage, environmental and industrial process markets worldwide.
“In 2007, we identified MODA technology as a result of our own internal needs to seek out automated tools that would help improve productivity and regulatory compliance,” explains Doug Danne, Head of Lonza’s Rapid Testing Solutions business unit. “MODA-EM™ informatics platform offered intelligent, real-time solutions and user-friendly trending tools that improved our Return on Investment (ROI). Lonza provided a unique resource of being an expert user of the product, and we are excited to explore new applications of MODA’s mobile data acquisition technology, both internally at Lonza as well as for our external customers.”
“We are very excited to be part of the Lonza family,” says Mike Desiderio, MODA CEO. “Our shared vision for a comprehensive analytics platform is now a reality, providing the industry a clear path to enhanced compliance, improved efficiencies and expedited decision making.”
The implementation of MODA’s technology will begin at Lonza’s manufacturing locations globally. Going forward, customer sites will be fully supported through Lonza’s Global Solutions Support team, offering hands-on installation, accelerated validation as well as training services.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.
More science. Less paper. MODA provides a mobile data acquisition platform that enables quality assurance and quality control organizations in the Life Sciences industry to automate their regulated manufacturing processes, including environmental monitoring (EM), utility testing, and product testing. MODA’s flagship software, MODA-EM™ informatics platform, is a paperless QC Micro solution that leverages mobile computing technology and advanced visualization tools for increased operational efficiency, improved quality, and reduced costs. MODA enables companies to advance their Green Initiatives by reducing and eventually eliminating the need for paper-based, labor-intensive EM programs. MODA is headquartered in Wayne, Pennsylvania with authorized resellers and technology integration partners throughout North America and Europe. For more information, visit www.modatp.com.
For further information
Lonza Group Ltd
Head Corporate Communications
Tel +41 61 316 8624
Fax +41 61 316 9624
Lonza Group Ltd
Tel +41 61 316 8798
Fax +41 61 316 9798
Lonza Group Ltd
Tel +41 61 316 8540
Fax +41 61 316 9540